A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are risk factors for cancer [1] [2] [3] . Epidemiological and animal studies provide evidence that a high-fat diet can be associated with an increased risk for cancer, in particular colorectal, breast, pancreatic and prostate cancer 3 . Arachidonic acid is one major ingredient of animal fats and the biologically active lipids derived from this substrate have crucial roles in chronic inflammation and cancer. The metabolism of arachidonic acid by cyclooxygenase (COX), lipoxygenase (LOX) and P450 epoxygenase pathways generates eicosanoids, including prostanoids, leukotrienes, hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and hydroperoxyeicosatetraenoic acids (HPETEs) (FIG. 1) . Epidemiological, clinical and animal studies provide evidence that activation of COX and LOX pathways during chronic inflammation and carcinogenesis results in aberrant metabolism of arachidonic acid, which may be one mechanism for the contribution of dietary fats to carcinogenesis.
. Arachidonic acid is one major ingredient of animal fats and the biologically active lipids derived from this substrate have crucial roles in chronic inflammation and cancer. The metabolism of arachidonic acid by cyclooxygenase (COX), lipoxygenase (LOX) and P450 epoxygenase pathways generates eicosanoids, including prostanoids, leukotrienes, hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and hydroperoxyeicosatetraenoic acids (HPETEs) (FIG. 1) . Epidemiological, clinical and animal studies provide evidence that activation of COX and LOX pathways during chronic inflammation and carcinogenesis results in aberrant metabolism of arachidonic acid, which may be one mechanism for the contribution of dietary fats to carcinogenesis.
Non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have beneficial effects on reducing the risk of developing some solid tumours, including the four most prevalent cancers worldwide: breast, colon, lung and prostate cancer 4 . NSAIDs exert some of their anti-inflammatory and anti-tumour effects by reducing prostanoid production through the inhibition of COX enzyme activity. In addition, emerging evidence suggests that LOX pathways are also involved in carcinogenesis. In general, 5-LOX (also known as ALOX5) and 12-LOX (also known as ALOX12) have potential procarcinogenic roles, whereas 15-LOX-2 (also known as ALOX15B) is thought to have an anti-carcinogenic effect, and the role of 15-LOX-1 (also known as ALOX15) remains controversial 5 . As 5-LOX has been shown to have a major role in carcinogenesis, understanding the contribution of each COX-derived prostanoid and 5-LOX-derived leukotriene in the pathogenesis of cancer could enable identification of new and safer therapeutic and chemopreventive agents with reasonable benefit and fewer side effects.
In this Review, we focus on recent insights into the roles of prostanoids and leukotrienes in several epithelial-derived malignancies, from their involvement in governing tumour epithelial cell proliferation, survival, and migration and invasion to their involvement in adapting the tumour microenvironment by influencing angiogenesis, inflammation and immunosuppression.
Prostanoid and leukotriene biosynthesis
The importance of the prostanoid and leukotriene biosynthetic pathway in carcinogenesis and chronic inflammation is supported by population studies, clinical trials and animal experiments. COX enzymes (correctly referred to as prostaglandin G/H synthases) exist in two isoforms: COX1 (also known as PTGS1) and COX2 (also known as PTGS2). COX2 is an immediate-early response gene that is normally absent from most cells but is highly induced at sites of inflammation and during tumour progression 6 . Our laboratory was the first to report that COX2 expression is upregulated in colorectal cancer
Cysteinyl leukotriene (CysLT) Leukotriene that contains the amino acid cysteine conjugated to the lipid backbone.
homeostasis. However, upregulation of COX1 expression has been observed in ovarian cancer 9 . Although most attention has been focused on the cyclooxygenase pathway, a few reports have indicated that 5-LOX is generally absent in normal epithelia but is induced by pro-inflammatory stimuli and is often constitutively expressed in various epithelial cancers including those of the colon, oesophagus, lung, prostate and breast 5 . As other LOX isoforms are not involved in leukotriene synthesis, the relevance of their expression and function is not included in this Review.
Prostanoid biosynthesis. Cyclooxygenase enzymes catalyse the conversion of arachidonic acid to prostanoids, including prostaglandins and thromboxane A 2 (TXA 2 ) (FIG. 1) . The prostaglandins exert their biological effects in an autocrine or paracrine manner by binding to their cognate cell surface receptors, which belong to the G protein-coupled receptor (GPCR) family. These receptors are designated DP (also known as PTGDR) and GPR44 for prostaglandin D 2 (PGD 2 ); EP1, EP2, EP3 and EP4 (also known as PTGER1, PTGER2, PTGER2 and PTGER4, respectively) for PGE 2 ; FP (also known as PTGFR) for PGF 2α ; IP (also known as PTGIR) for PGI 2 ; and TP (also known as TBXA2R) for TXA 2 . In some cases, however, certain prostaglandins and their metabolites bind nuclear receptors such as peroxisome proliferator-activated receptors (PPARs). For example, PGI 2 can transactivate PPARδ, and a PGD 2 dehydration product, 15-deoxy-Δ12,14-PGJ 2 (15dPGJ 2 ), is a natural ligand for PPARγ. PGE 2 can also indirectly activate PPARδ in certain contexts 10 . The specific action of the different prostaglandins in a particular type of tissue predominantly depends on the cell type-specific expression of their cognate receptors as well as prostaglandin production. In addition to their synthesis, the steady-state extracellular levels of prostaglandins also depend on a carrier-mediated transport process, as well as inactivation in the cytoplasm. These processes are regulated by prostaglandin transporter (PGT; an influx transporter), multidrug resistance-associated protein 4 (MRP4; an efflux transporter) and hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD; also known 15-PGDH). For example, PGE 2 and PGF 2α are rapidly metabolized in vivo by 15-PGDH to a stable 13,14-dihydro-15-keto-PGE 2 (PGEM) and 13,14-dihydro-15-keto-PGF 2α , respectively. Other prostaglandins are mainly metabolized in a non-enzymatic manner 11 .
Leukotriene biosynthesis. The 5-LOX enzyme interacts with a 5-LOX-activating protein (FLAP) and converts arachidonic acid to the unstable leukotriene A 4 (LTA 4 ) through an HPETE. FLAP enhances the activity of 5-LOX by binding to arachidonic acid and presenting it to 5-LOX. LTA 4 is subsequently converted to 5-HETE, or hydrolysed into biologically active LTB 4 by LTA 4 hydrolase, or to the cysteinyl leukotriene (CysLT), LTC 4 , by LTC 4 synthase. LTC 4 is then converted to another CysLT, LTD 4 , which is sequentially metabolized to LTE 4 (FIG. 1) . LTB 4 and LTD 4 are the most potent leukotrienes. They exert their biological effects through the activation of GPCRs. LTB 4 can bind to two receptors, BLT1 (also known as LTB4R) with high affinity and BLT2 (also known as LTB4R2) with low affinity; CysLTs bind to at least two distinct receptors, CysLT1 (also known as CYSLTR1) and CysLT2 (also known as CYSLTR2). Like LTB 4 receptors, CysLT1 has a high affinity for CysLTs -which is higher for LTD 4 than LTC 4 -whereas CysLT2 has a lower overall affinity for CysLTs that is equal for LTD 4 and LTC 4 . BLT1 and CysLT1 are exclusively expressed in leukocytes, whereas BLT2 and CysLT2 are expressed in a wide variety of cells.
Transcellular biosynthesis.
Eicosanoid biosynthesis can occur in a single cell that contains the complete complement of enzymes, but the production of eicosanoids in a tissue, in particular in tumour tissues and sites of inflammation, takes place in a more complex manner in which some of these biologically active lipids, specifically leukotrienes, are generated by transcellular biosynthesis through the cooperation of multiple different cell types.
The leukotrienes are primarily produced by stimulated leukocytes that express the enzymes required for their synthesis. Epithelial and endothelial cells can also generate LTB 4 , LTC 4 and LTD 4 at inflammatory sites through transcellular metabolism by which epithelial or endothelial cells use LTA 4 that is released from immune cells, in particular neutrophils, as epithelial and endothelial cells express LTA 4 hydrolase 12 . However, leukocytes can also use arachidonic acid that is secreted from epithelial cells as a substrate to generate leukotrienes. Transcellular leukotriene biosynthesis has been observed during inflammation in vivo 13 . Therefore, the transcellular biosynthesis
At a glance
• The altered metabolism of arachidonic acid by cyclooxygenase (COX) and lipoxygenase (LOX) is a common feature of several epithelial-derived malignancies and has been shown to have crucial roles in cancer progression.
• The production of arachidonic acid-derived prostanoids and leukotrienes occurs in single cells or takes place in a complex manner in which these biologically active lipids, specifically leukotrienes, are generated by transcellular biosynthesis through the cooperation of multiple different types of cells in the tumour and inflamed tissues.
• Pro-inflammatory prostaglandins and leukotrienes promote tumour growth by regulating tumour epithelial cells themselves and orchestrating the complex interactions between transformed epithelial cells and surrounding stromal cells to establish the tumour microenvironment that facilitates tumour-associated angiogenesis and evades attack by the immune system.
• Prostaglandins and leukotrienes can modulate tumour epithelial cell proliferation, apoptosis, and migration and invasion through multiple signalling pathways in both an autocrine and paracrine fashion.
• Prostaglandins and leukotrienes are central molecules in the regulation of stem cell homeostasis.
• Pro-inflammatory prostaglandins and leukotrienes are key mediators in the crosstalk between tumour epithelial cells and their surrounding stromal cells in establishing a tumour microenvironment with chronic inflammation and immunosuppression.
• Eicosanoids in cancer Prostanoids and cancer. Among prostanoids, proinflammatory PGE 2 has a predominant role in promoting tumour growth. PGE 2 is the most abundant prostaglandin that is found in various human malignancies, including colon, lung, breast, and head and neck cancer, and is often associated with a poor prognosis [14] [15] [16] [17] . By contrast, 15-PGDH is highly expressed in normal tissues but is ubiquitously lacking in human colon, gastric, lung and breast cancer [18] [19] [20] [21] . Min/+ mice and significantly enhanced AOM-induced colon tumour incidence and multiplicity 10, 24 . Furthermore, increased endogenous PGE 2 through the genetic deletion of 15-Pgdh promotes colon tumour growth in Apc Min/+ and AOM mouse models 25 . By contrast, inhibition of endogenous PGE 2 through the genetic deletion of prostaglandin E synthase (Ptges) Figure 1 | an overview of eicosanoid synthesis pathways. Arachidonic acid is a polyunsaturated fatty acid that constitutes the phospholipid domain of most cell membranes and is liberated from the cellular membranes by cytoplasmic phospholipase A2 (PLA2). Free arachidonic acid can be metabolized to eicosanoids through three major pathways: the cyclooxygenase (COX), the lipoxygenase (LOX) and the cytochrome P450 monooxygenase pathways. In the COX pathway, the key step is the enzymatic conversion of arachidonic acid to the intermediate prostaglandin G 2 (PGG 2 ), which is then reduced to an intermediate PGH 2 by the peroxidase activity of COX. PGH 2 is sequentially metabolized to prostanoids, including prostaglandins (PGs) and thromboxanes (TXs) by specific prostaglandin and thromboxane synthases. LOXs convert arachidonic acid into biologically active metabolites such as leukotrienes and hydroxyeicosatetraenoic acids (HETEs); P450 metabolizes arachidonic acid into epoxyeicosatrienoic acids (EETs), HETEs and hydroperoxyeicosatetraenoic acids (HPETEs). In the 5-LOX pathway, arachidonic acid is converted to an intermediary 5-HPETE, which is further metabolized to form the unstable leukotriene A 4 (LTA 4 ). LTA 4 is subsequently converted to 5-HETE, LTB 4 , LTC 4 , LTD 4 and LTE 4 . Each of the prostaglandins and leukotrienes exerts its biological effects by binding to its cognate G protein-coupled receptor. PGI 2 can transactivate the nuclear peroxisome proliferator-activated receptor-δ (PPARδ), and a PGD 2 dehydration product, 15dPGJ 2 , is a natural ligand for PPARγ. The multidrug resistance-associated protein (MRP) gene family is comprised of efflux transporters for both prostaglandins and leukotrienes, and PGT is an influx transporter for prostaglandins. Hydroxyprostaglandin dehydrogenase 15-(NAD) (15-PGDH) mainly metabolizes intracellular PGE 2 and PGF 2α to a stable 13,14-dihydro-15-keto-PGE 2 and 13,14-dihydro-15-keto-PGF 2α . The red boxes indicate the signalling pathways that are discussed in this Review. CysLT, cysteinyl leukotriene; NSAID, non-steroidal anti-inflammatory drug.
suppresses intestinal tumorigenesis in Apc
Min/+ and AOM models 26 . The central role of PGE 2 in colorectal tumorigenesis has been further confirmed by evaluating mice with a homozygous deletion of individual PGE 2 receptors [27] [28] [29] . Limited information is available regarding the role of PGE 2 signalling in animal models of other cancers. Increased PGE 2 levels through the overexpression of COX2 and PTGES cause gastric tumorigenesis in Wnt1-transgenic mice driven by the keratin 19 (Krt19) promoter 30 . Deletion of the EP2 receptor inhibits murine lung tumorigenesis that is induced by a chemical carcinogen 31 and significantly suppresses COX2-induced mammary hyperplasia in mice 32 . Similarly, an EP1 antagonist inhibits chemically induced breast cancer development in rats 33 .
Collectively, these studies demonstrate that PGE 2 plays an important part in cancer progression.
The role of PGD 2 in carcinogenesis remains ambiguous. Disruption or overexpression of PGD 2 synthase (PTGDS) in Apc Min/+ mice accelerates or reduces intestinal tumour growth 34 , suggesting that PGD 2 has anti-tumour effects. However, the evidence that genetic disruption of its receptor (DP) has no effect on colon tumour formation in the AOM mouse model does not support the hypothesis that PGD 2 has anti-tumour effects 28 . One possible explanation for the differences in phenotype caused by PTGDS compared with DP in mouse models is that the PGD 2 -derived product 15dPGJ 2 inhibits tumour growth by binding to PPARγ. It is well established that the activation of PPARγ inhibits tumour growth through anti-proliferative, pro-apoptotic, pro-differentiation and anti-angiogenic effects in cell lines and animal models 35 . Alternatively, overexpression of PTGDS might shift the conversion of PGH 2 away from PGE 2 , which in turn would suppress tumour growth. Further investigation is required to assess the role of PGD 2 and its receptors in cancer progression.
Little information regarding the role of other prostaglandins in animal models of cancer is available; however, disruption of FP, IP or TBXA2R receptors does not affect colon tumour formation in the AOM mouse model 28 , suggesting that these receptors are not involved in CRC progression. The question is now whether these receptors modulate tumour growth in other models of CRC or in other types of cancer. A role for PGF 2α in tumorigenesis has been suggested as it can enhance carcinogen-induced transformation of fibroblasts in vitro through the induction of COX2 (ReF. 36) . Activation of PPARδ accelerates intestinal tumour growth in Apc Min/+ mice 37 , supporting the idea that PGI 2 might promote colon tumour progression through this receptor. Further work is required to explore the role of PGI 2 in colon carcinogenesis and other cancers.
Leukotrienes and cancer.
Compared with prostaglandins, much less is known about the pro-inflammatory leukotrienes in cancer. However, emerging data suggest that leukotrienes can have an important role in carcinogenesis.
LTB 4 levels are increased in human colon and prostate cancer 38, 39 , and the expression of LTB 4 receptors is increased in human pancreatic cancer 40 . LTB 4 expression is also increased in HRAS-v12-transformed cells and the receptor BLT2 is required for Ras-induced transformation in vivo 41 . Furthermore, inhibition of LTB 4 synthesis by treatment with an LTA 4 hydrolase inhibitor, bestatin, reduced the burden of oesophageal adenocarcinoma in a rat model 42 . The CysLT1 receptor is highly expressed in human colon and prostate cancers and negatively correlates with patient survival 43, 44 . Increased CysLT1 expression in CRC correlates with the ability of LTD 4 to induce proliferation and inhibit apoptosis. By contrast, reduced expression of the CysLT2 receptor is associated with a poor prognosis in patients with CRC, and CysLT2 signalling is involved in inducing apoptosis and terminal differentiation 45 . However, comparatively little is known about the effects of CysLT2 on signalling and biological function.
Mechanisms of eicosanoids in carcinogenesis
To understand the mechanism(s) underlying the effects of prostaglandins and leukotrienes on cancer progression, researchers have been investigating precisely how these lipids affect cancer biology. As mentioned earlier, pro-inflammatory eicosanoids are abundantly produced by various types of cancer cells and their surrounding cells. These biologically active lipids can modulate tumour progression through several mechanisms, such as by directly activating their receptors on tumour epithelial cells to regulate cell proliferation, apoptosis, migration and invasion; directly inducing epithelial cells to secrete growth factors, pro-inflammatory mediators and angiogenic factors that switch a normal microenvironment to one that supports tumour growth and spread; and directly binding receptors on stromal cells to promote a tumour-supportive microenvironment by inducing angiogenesis and evading attack by the immune system (FIG. 2) .
The role of prostaglandins and leukotrienes in tumour epithelial cells. Prostaglandins and leukotrienes can modulate tumour cell proliferation, differentiation and apoptosis through multiple signalling pathways in both an autocrine and paracrine fashion (FIG. 3 ; TABLe 1). PGE 2 induces proliferation by activating at least two signalling pathways: Ras-Erk and glycogen synthase kinase-3β (GSK3β)-β-catenin in colon and lung cancer cells [46] [47] [48] . In breast cancer, PGE 2 can upregulate aromatase production in stromal fat cells and concomitantly oestrogen production, which stimulates tumour cell proliferation 49 . In addition, PGE 2 promotes colon tumour cell survival by activating a PI3K-Akt-PPARδ cascade in Apc Min/+ mice 10 . PGE 2 upregulation of BCL-2, an anti-apoptotic protein, and induction of nuclear factor-κB (NF-κB) transcriptional activity might also be involved in PGE 2 -induced inhibition of apoptosis 50, 51 . Similarly, PGF 2α induces cell proliferation through an FP-Erk-fibroblast growth factor 2 (FGF2)-FGF receptor 1 (FGFR1)-Erk cascade in endometrial tumour cell lines 52 . By contrast, PGD 2 secreted by stromal cells inhibits prostate tumour cell growth in vitro through a PPARγ-dependent mechanism 53 . Nature Reviews | Cancer 
Normal microenvironment
Knock down of LTA 4 hydrolase inhibits anchorageindependent growth of HCT-116 colon cancer cells, suggesting that leukotrienes are involved in cell growth regulation 54 . Indeed, LTA 4 hydrolase-derived LTB 4 stimulates cell proliferation and promotes cell survival through a BLT1-Erk pathway in colon tumour cell lines 55 , and induces cell proliferation through both Mek-Erk and PI3K-Akt pathways in human pancreatic cancer cell lines 56 . Activation of the LTD 4 -CysLT1 axis promotes cell proliferation and survival through multiple parallel pathways such as GSK3β-β-catenin, protein kinase C (PKC)-Raf-ERK1 and ERK2, BCL-2 and COX2 in nontransformed human intestinal epithelial cell lines [57] [58] [59] and induces cell proliferation but not survival in CRC cell lines 60 . By contrast, inhibition of LTD 4 signalling by a CysLT1 antagonist can induce apoptosis in prostate cancer cell lines 44 . The LTD 4 induction of COX2, as well as PGE 2 production, implies that crosstalk exists between the 5-LOX and COX2 pathways. Consistent with the negative correlation of CysLT 2 expression with a poor prognosis in patients with CRC, CysLT 2 signalling leads to terminal differentiation and growth inhibition in colon carcinoma cell lines 45 . In addition, prostaglandins and leukotrienes also affect the migration and invasion of carcinoma cells. Our group has demonstrated that PGE 2 induces CRC cell migration and invasion through epidermal growth factor receptor (EGFR)-PI3K-Akt signalling in vitro 61 . Subsequently, we found that PGE 2 induction of an EP4-β-arrestin 1-SRC complex was crucial in transactivating EGFR to induce downstream Akt signalling and stimulate CRC cell migration in vitro, as well as the metastatic spread of disease to the liver in vivo 62 . The SRC-EGFR pathway also mediates PGE 2 -induced human hepatocellular carcinoma cell invasion in vitro 63 . These studies revealed that activation of PGE 2 receptors transactivates EGFR through an intracellular mechanism. It has been reported that PGE 2 transactivation of EGFR depends on the extracellular release of an EGFlike ligand in vitro 64 . PGE 2 can also induce cell migration and invasion through other signalling pathways, including the induction of matrix metalloproteinase 2 (MMP2) through an Erk-ETS1 cascade in pancreatic cancer cell lines 65 and the upregulation of C-C chemokine receptor 7 (CCR7) through EP2 and EP4 in breast cancer cell lines 66 . In addition, treatment with an EP4 antagonist inhibits lung carcinoma cell migration and invasion in vitro and in vivo 67 . Similar to PGE 2 , PGF 2α also stimulates motility and invasion of colon 68 and endometrial 69 carcinoma cell lines and TXA 2 of prostate carcinoma cell lines 70 . Relatively little is known about the ability of leukotrienes to regulate tumour cell migration and invasion. In an in vivo study, an LTB 4 antagonist was shown to inhibit the metastatic spread of pancreatic cancer cells to the liver and other organs 71 . In an in vitro study, LTD 4 induced non-transformed intestinal cell migration through the activation of a PI3K-Rac cascade 72 . Solid tumours are thought to originate from a single replication-competent cell (stem cell or proliferative progenitor cell) 1 . Recent studies have established that both prostaglandins and leukotrienes are central molecules in the regulation of stem cell homeostasis. PGE 2 protects mouse embryonic stem cells from undergoing apoptosis through an EP2-PI3K-Akt cascade 73 and regulates growth and development of both embryonic haematopoietic stem cells and adult stem cells in several different organisms 74, 75 . Similarly, LTB 4 and LTD 4 [76] [77] [78] [79] . Collectively, the novel functions of these biologically active lipids on stem cell growth and maturation might suggest their ability to regulate cancer stem cell growth. This deserves considerable attention, and future research must be directed towards obtaining a better understanding of the role of prostaglandins and leukotrienes in regulating progenitor cells in solid tumours.
Dendritic cells
The role of eicosanoids in the inflammatory microenvironment. Chronic inflammation causes stromal cells to produce pro-inflammatory mediators, including eicosanoids, cytokines and chemokines, that shift the tissue microenvironment from normal to aberrant. In general, the inflammatory microenvironment, which is associated with changes in leukocyte profiles as well as their functionality, can initiate epithelial cell transformation and promote tumour growth, angiogenesis and metastasis 80 . A growing body of evidence demonstrates that prostaglandins and leukotrienes are key immunomodulators mediating the crosstalk between epithelial cells and their surrounding stromal cells in the tumour microenvironment (FIG. 4) .
The normal presence and trafficking of immune cells into the mucosal compartment has been termed physiological inflammation. In response to tumour-associated or chronic inflammation, transformed or normal epithelial cells and tissue-resident immune cells locally secrete cytokines, chemokines and pro-inflammatory eicosanoids that recruit additional leukocytes from the circulation into the tissue. The common pathological changes associated with chronic inflammation include increased infiltration of dysregulated immune cells, production of pro-inflammatory mediators, diminished epithelial integrity and deficient feedback systems that normally downregulate the mucosal response to antigens. Furthermore, the immune cells recruited to the tumour microenvironment are phenotypically different from the normal immune cells and can maintain inflammation and induce angiogenesis 80 . For example, the massively recruited macrophages in the mucosa of active inflammatory bowel disease (IBD) are phenotypically different from normal macrophages and have a major role in chronic mucosal inflammation by secreting many pro-inflammatory cytokines 81 . Although epidemiological and experimental evidence strongly implicates chronic inflammation as a risk factor for cancer, the mechanisms by which inflammation and inflammatory mediators result in neoplastic transformation and progression have not been completely resolved. A strong association between chronic inflammation and malignant diseases occurs in CRC that arises in patients with IBD. The role of PGE 2 in IBD is the best characterized example of the role of prostaglandins in chronic inflammation. PGE 2 exacerbates inflammation and disease severity through increasing the infiltration of neutrophils and T helper 17 (T H 17) cells to the colonic tissue in a murine model of IBD 82 . Several lines of evidence further suggest that PGE 2 -induced expansion of inflammatory T H 17 cells depends on the involvement of T cells and dendritic cells. PGE 2 shifts the interleukin-12 (IL-12)/IL-23 balance in dendritic cells through EP2 and EP4 receptors in favour of IL-23, which in turn increases the number of T H 17 cells in vitro 82 . IL-12 promotes T helper 1 (T H 1) responses and suppresses T H 17 development and function, whereas IL-23 is essential for T H 17 expansion and survival. PGE 2 also facilitates IL-23-induced T H 17 expansion from peripheral blood mononuclear cells and naive T cells in vitro 83, 84 , induces T H 1 cell differentiation in vitro and promotes inflammation through T H 1 and T H 17 cells in an animal model of chronic inflammation through the EP4 receptor 85 . In addition, PGE 2 induces dendritic cell migration in vitro by upregulation of CCR7 (ReF. 86) . By contrast, PGD 2 inhibits the migration of dendritic cells to the lymph nodes in vivo 87 . During chronic inflammation, dendritic cells secrete large amounts of inflammatory cytokines that further recruit monocytes and immature dendritic cells into inflamed tissues.
Leukotrienes are powerful lipid mediators of inflammation in various acute and chronic inflammatory and allergic diseases, including IBD 88 . In fact, urinary LTE 4 can serve as a biomarker for IBD 89 . Similar to chemokines, LTB 4 is another potent chemoattractant and activator of neutrophils, eosinophils, basophils, T cells, Multiple cellular signalling pathways mediate the effects of prostaglandin E 2 (PGE 2 ) and leukotriene B 4 (LTB 4 ) on the regulation of epithelial tumour cell proliferation, survival, and migration and invasion. PGE 2 stimulates cell proliferation through multiple cascades in both colorectal cancer (CRC) and non-small-cell lung cancer cells. PGE 2 also induces cell proliferation through a glycogen synthase kinase-3β (GSK3β)-β-catenin (β-cat) pathway in CRC cells or by the upregulation of aromatase in breast cancer cells. PGE 2 inhibition of GSK3β reduces β-catenin phosphorylation and thereby prevents its degradation, leading to accumulation, nuclear translocation and functional activity of β-catenin. PGE 2 promotes CRC cell survival by activating a PI3K-Akt-peroxisome proliferator-activated receptor-δ (PPARδ) cascade in vitro and in vivo. In addition, PGE 2 induces CRC cell migration and invasion through β-arrestin-1-SRC-epidermal growth factor receptor (EGFR)-PI3K-Akt signalling in vitro and in vivo. PGE 2 transactivation of EGFR also depends on the extracellular release of an EGF-like ligand in CRC cell lines and a normal gastric epithelial cell line. PGE 2 also induces cell migration and invasion through an Erk-ETS1-matrix metalloproteinase 2 (MMP2) cascade in pancreatic cancer cell lines or through the upregulation of C-C chemokine receptor 7 (CCR7) in breast cancer cell lines. LTB 4 stimulates cell proliferation and promotes cell survival through a BLT1-Erk pathway in CRC cell lines or through both Mek-Erk and PI3K-Akt pathways in human pancreatic cancer cell lines. P, phosphorylation. 
Regulatory T cells
A T cell subpopulation that suppresses activation of other T cells and maintains immune system homeostasis and peripheral tolerance to self-antigens.
Myeloid-derived suppressor cells (MDSCs)
Immature myeloid cells with potent immunosuppressive functions.
dendritic cells and macrophages in inflammatory sites [90] [91] [92] [93] ; a Rac-Erk signalling cascade might also be responsible for LTB 4 -induced chemotaxis 94 . Similar to PGE 2 , LTB 4 promotes the migration of dendritic cells though the upregulation of CCR7 in vitro and in vivo 95 . However, it is not clear whether Rac-Erk signalling mediates LTB 4 -induced CCR7 expression. Collectively, these studies show that pro-inflammatory prostaglandins and leukotrienes could stimulate tumour growth through establishing an inflammatory microenvironment. (FIG. 5) . PGE 2 helps to shift the tumour microenvironment from anti-tumour T H 1 responses to immunosuppressive T helper 2 (T H 2) responses by downregulation of T H 1 cytokines (tumour necrosis factor-α (TNFα), interferon-γ (IFNγ) and IL-2) and upregulation of T H 2 cytokines (IL-4, IL-10 and IL-6) in immune cells [96] [97] [98] . Moreover, PGE 2 directly inhibits the activity of cytotoxic T cells through the upregulation of a CD94 and NKG2A complex and induces regulatory T cell function in vitro 99, 100 . PGE 2 produced by tumour cells can also indirectly abolish the antitumour effects of cytotoxic T cells in vivo and in vitro through the downregulation of both direct antigen presentation by tumour cells and cross-presentation by dendritic cells 101 . For example, an in vitro study showed that PGE 2 switches the function of dendritic cells from induction of immunity to T cell tolerance through the upregulation of CD25 and indoleamine 2,3-dioxygenase 102 . In addition to modulating T cell BLT1, leukotriene B4 receptor (also known as LTB4R); CCR7, C-C chemokine receptor 7; COX2, cyclooxygenase 2; CysLT1, cysteinyl leukotriene receptor 1; EGFR, epidermal growth factor receptor; EP1, prostaglandin E receptor 1; FGF2, fibroblast growth factor 2; FGFR1, FGF receptor 1; FP, prostaglandin F receptor; GSK3b, glycogen synthase kinase 3b; LTB 4 , leukotriene B 4 ; NF-kB, nuclear factor-kB; PGE 2 , prostaglandin E 2 ; PKC, protein kinase C; PPARd, peroxisome proliferator-activated receptor-d; TXA 2 
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Cross-presentation
A mechanism by which a professional antigen-presenting cell takes up, processes and presents extracellular antigens from a third cell (for example, a virus-infected or tumour cell) with major histocompatibility complex class I molecules to activate a naive CD8 + T cell.
T cell tolerance
Unresponsiveness of the adaptive immune system to antigens, as a result of the inactivation or death of antigen-specific T cells, which is induced by exposure to the antigens. and dendritic cell function, PGE 2 modulates cancerassociated immunosuppression through the inhibition of dendritic cell differentiation and T cell proliferation in vivo 103, 104 . Furthermore, PGE 2 promoted mammary tumour progression through the induction of MDSCs in vivo 105 . Collectively, the effects of PGE 2 on the immune system may allow neoplastic cells to evade attack. To our knowledge, there is nothing further reported in the literature indicating the participation of other prostaglandins and leukotrienes in cancer-associated immunosuppression.
Apc
Angiogenesis. It is widely recognized that angiogenesis is required for tumours to grow beyond a certain size and to metastasize. To develop a stable blood supply for tumour growth, many cells in the tumour microenvironment, including tumour epithelial cells, stromal cells and immune cells, secrete various proangiogenic factors that stimulate endothelial cell recruitment, proliferation, migration and tubule formation. Numerous in vitro and in vivo studies indicate that prostaglandins and leukotrienes modulate angiogenesis at different levels (FIG. 6) .
Homozygous deletion of Ep2 completely abrogates the induction of vascular endothelial growth factor (vEGF) in the intestinal polyp stroma of Apc Δ716 mice and inhibits intestinal polyp growth, demonstrating that PGE 2 induction of vEGF is important for tumour growth in this mouse model 29 . Moreover, PGE 2 induced expression of CXCL1, a pro-angiogenic chemokine, in human CRC cells, and the release of CXCL1 from tumour epithelial cells in turn stimulated microvascular endothelial cell migration and tube formation in vitro and in vivo 106 . Activation of EP2 receptors by PGE 2 induces FGF2 expression through potential multiple protein kinase A (PKA), SRC, EGFR, and ERK1 and ERK2 signalling pathways in an endometrial adenocarcinoma cell line and in endometrial 
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Chick chorioallantoic membrane system
A biological assay using the well-vascularized chorioallantoic membrane of the chicken egg to evaluate the biological activity of pro-angiogenic and anti-angiogenic factors.
adenocarcinoma tissue explants 107 . PGE 2 released from mammary tumour epithelial cells induces angiogenesis through the induction of pro-angiogenic factors through a cyclic AMP-dependent PKA pathway in vivo and in vitro 108 . PGE 2 can also induce vEGF secretion in ovarian, prostate and gastric cancer cell lines through the activation of EGFR downstream of EP2 and EP4 (ReFS 109-111 ). Similar to PGE 2 , PGF 2α induces vEGF expression through an FP-EGFR-Ras-Erk pathway in an endometrial adenocarcinoma cell line 112 . Moreover, PGF 2α -FP signalling can stimulate the secretion of CXCL1 in endometrial tumour cells to promote neutrophil infiltration in mouse xenograft tumours 113 ; neutrophil infiltration has also been shown to be essential for angiogenesis in other tumour models 114 . In tumour implantation models, increased TXA 2 levels as a result of overexpression of TXA 2 synthase in colon-26 adenocarcinoma cells accelerated tumour growth and tumour-associated angiogenesis in syngeneic BALB/c mice 115 . In addition to inducing the production of angiogenic factors in epithelial cells, prostaglandin signalling in stromal cells also contributes to angiogenesis. A host PGE 2 -EP2 signal is required for tumour angio genesis by enhancing endothelial cell motility and vascular hyperpermeability in a mouse model of breast cancer 116 . Similarly, the host PGE 2 -EP3 signal is a prerequisite for vEGF expression in the stroma and tumour angiogenesis in a mouse model of lung carcinoma 117 . In endothelial cells, PGE 2 not only upregulates vEGF and FGF2 expression through the stimulation of an ERK2-JuN N-terminal kinase 1 (JNK1) signalling pathway, which is important for inducing cell growth and survival 118 , but also promotes αvβ3 integrin-dependent migration and spreading of endothelial cells 119 and mediates vEGF-and FGF2-induced CXCR4-dependent neovessel assembly in vivo 120 . In addition, TXA 2 mediates the effects of COX2 on endothelial cell migration and angiogenesis in vitro and in vivo 121 . Intriguingly, vEGF and FGF2 induce COX2, and subsequently PGE 2 and PGI 2 , in endothelial cells, suggesting that the effects of PGE 2 on regulation of vEGF and FGF2 are probably amplified through a positive feedback loop 120 . In contrast to PGE 2 signalling, deficiency of the DP receptor in the host accelerates tumour growth of implanted lung carcinomas by stimulating angiogenesis 122 , suggesting that the host PGD 2 -DP signal inhibits tumour growth by inhibiting angiogenesis.
The physiological significance of leukotrienes in angiogenesis is much less well characterized than that of the prostaglandins. LTB 4 induced endothelial cell migration and tube formation in vitro and stimulated vEGF-induced angiogenesis through the BLT2 receptor in vivo 123 . Similarly, LTC 4 induced endothelial cell proliferation in vitro 124 and LTC 4 and LTD 4 promoted angiogenesis in the chick chorioallantoic membrane system 125 . In addition, LTB 4 enhances hypoxia-induced microvascular alterations in vivo 126 . In addition to the involvement of PGE 2 and leukotrienes in signalling crosstalk between tumour epithelial and endothelial cells, PGE 2 also stimulates immune cells to produce pro-angiogenic factors. For example, PGE 2 promotes mast cells to release vEGF and the chemokine CCL2 in vitro 127, 128 . CCL2 can induce tumour-associated angiogenesis 129 by directly recruiting endothelial cells that express its receptor CCR2 in vitro and in vivo 130 , by inducing vEGF release from macrophages through a COX2-PGE 2 pathway in vitro 131 , and/or by indirectly attracting more tumour-associated monocytes and macrophages, which are phenotypically distinct from normal macrophages in their ability to promote angiogenesis in mice 132 . LTB 4 induces neutrophil-mediated vascular permeability in vitro and in vivo 133 . Moreover, inhibition of CysLT production by the deletion of LTC 4 synthase reduces vascular permeability in zymosan A-induced, monocyte and macrophage-mediated peritoneal inflammation and in immunoglobulin E-dependent, mast cell-mediated passive cutaneous anaphylaxis 134 , suggesting that CysLTs promote inflammation-mediated vascular permeability.
Therapeutic and chemopreventive agents A retrospective cohort study shows that aspirin, a nonselective NSAID, specifically reduces cancer risk in the subgroup of patients whose colon tumours expressed higher levels of COX2 (ReF. 135) . In addition to prevention, regular aspirin use after the diagnosis of CRC at stages I, II and III improves overall survival, especially among individuals whose tumours overexpress COX2 (ReF. 136) . However, the prolonged use of non-selective NSAIDs is associated with adverse gastrointestinal side effects. Long-term use of high doses of selective COX2 inhibitors is currently not recommended because of the unacceptable cardiovascular side effects in certain patients, especially those with a history of atherosclerotic heart disease 137 . However, a selective COX2 inhibitor (celecoxib) is still approved by the uS Food and Drug Administration for use as an adjuvant treatment in patients at a high risk for developing CRC, such as those with familial adenomatous polyposis. It has been proposed that some of the adverse effects related to NSAID use are associated with a global reduction in prostanoid production 138 . For instance, COX2 deficiency in mice contributes to the pro-atherogenic properties of high-density lipoprotein cholesterol, with increased lipid deposition in the aorta and the dramatic imbalance in circulating prostanoids 139 . One hypothetical method to avoid the cardiovascular side effects of COX2 inhibition would be to target only COX-derived PGE 2 signalling that mediates the tumour-promoting effects of COX2. For example, antagonists of PGE 2 receptors have been developed and show promising effects for preventing and/or inhibiting growth of different types of tumours, including colon, oesophageal, lung and breast in preclinical animal models [27] [28] [29] 33, 67, 140 . Inhibition of the 5-LOX pathway may also be useful for cancer therapy. For example, a 5-LOX inhibitor, zileuton, has been shown to prevent lung tumorigenesis in carcinogen-treated mice 141 . A combined treatment regimen using a selective COX2 inhibitor and a 5-LOX inhibitor not only had additive effects on reducing tumour growth in mouse xenograft models of human colon, oesophageal, breast and skin cancer [142] [143] [144] [145] , but also reduced liver metastases in a hamster model of chemically induced ductal pancreatic adenocarcinoma 146 . Moreover, blockage of leukotriene production by the LTA 4 hydrolase inhibitor bestatin reduced tumour burden in rats, as described above 42 . The LTB 4 receptor antagonist, LY293111, significantly inhibits tumour growth and metastases in a fluorescent orthotopic model of pancreatic cancer 71 and a mouse xenograft model of human CRC 147 . unfortunately, the results from two Phase II trials showed that LY293111 did not improve progressionfree survival in patients with non-small-cell lung or pancreatic cancer 148 . In addition, a CysLT1 receptor antagonist, zafirlukast, reduced tumour burden in a mouse model of carcinogen-induced lung tumours 149 . Although NSAIDs are still among the most promising chemopreventive agents for cancer, cardiovascular and gastrointestinal side effects have dampened enthusiasm for their use as chemopreventive agents. Therefore, it is now crucial to evaluate whether the antagonists of PGE 2 and leukotriene receptors have better specificity for human cancer prevention and treatment.
Summary
Many strategies exist to develop more effective cancer prevention and treatment options. Chemoprevention and targeted therapies are being carefully evaluated on several fronts as effective measures to achieve better cancer control. A big challenge remains to develop chemopreventive agents that are both effective and safe. An entirely new approach, referred to as personalized cancer prevention and treatment, is likely to have an important role in achieving these goals. This idea is supported by the observations that patients whose colon tumours express higher levels of COX2 benefit from regular aspirin use in cancer prevention and risk reduction 135, 136 , and that patients whose tumours express a mutant form of KRAS do not benefit from EGFR-specific therapy with cetuximab or panitumumab 150 . However, this approach relies on a foundation of knowledge derived from the molecular basis of carcinogenesis to the molecular characterization of individual cancers. understanding the role of eicosanoids in tumorigenesis and profiling these biologically active lipids in each patient are two crucial steps towards this personalized approach as they may be biomarkers for predicting which patients respond to NSAIDs in prevention and/or as intermediate markers for assessing response during treatment.
In addition to biomarkers, certain eicosanoids are also potential drug targets for personalizing cancer prevention and/or treatment. The evidence that proinflammatory eicosanoids such as PGE 2 , LTB 4 and LTD 4 promote tumour growth and metastasis, whereas anti-inflammatory PGD 2 suppresses tumour growth will provide a rationale to develop the next generation of personalized cancer preventive agents. Therefore, it is now crucial to evaluate whether these prostaglandin and leukotriene receptor antagonists and agonists, as well as agents that lower cellular levels of pro-inflammatory prostaglandins and leukotrienes, have better efficacy with fewer adverse effects than NSAIDs. For example, the activators of 15-PGDH and inhibitors of PGE 2 synthases, LTA 4 hydrolase and LTC 4 synthases may be useful agents for future studies.
